Arcus Biosciences And Gilead Halt STAR-221 Trial After Failing To Meet Efficacy Targets In Gastric Cancer
Biopharmaceutical companies Arcus Biosciences, Inc. (RCUS) and Gilead Sciences, Inc. (GILD) have jointly announced the termination of their Phase 3 STAR-221 trial, marking a setback in the development of combination immunotherapies for advanced gastrointestinal malignancies. The Independent Data Monitoring Committee recommended halting the study due to futility following a pre-planned interim analysis focused on overall survival outcomes.
The trial had been investigating whether combining
Biopharmaceutical companies Arcus Biosciences, Inc. (RCUS) and Gilead Sciences, Inc. (GILD) have jointly announced the termination of their Phase 3 STAR-221 trial, marking a setback in the development of combination immunotherapies for advanced gastrointestinal malignancies. The Independent Data Monitoring Committee recommended halting the study due to futility following a pre-planned interim analysis focused on overall survival outcomes.
The trial had been investigating whether combining